n.a. (HSP)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)

Latest News

Trade-Ideas: Hospira (HSP) Is Today's New Lifetime High Stock

Trade-Ideas: Hospira (HSP) Is Today's New Lifetime High Stock

Trade-Ideas LLC identified Hospira (HSP) as a new lifetime high candidate

10 Best S&P 500 Health Care Stocks

10 Best S&P 500 Health Care Stocks

So far in 2015, the health care sector has been outpacing the general market.

10 Best S&P 500 Stocks This Year

10 Best S&P 500 Stocks This Year

Stocks were rattled this week by Greece's impending default, causing the S&P 500 barely eek out a gain for the first half of the year. Netflix's stock has nearly doubled.

How Apple, Google and 7 Other Cash-Hoarding Companies Will Spend Their Billions

How Apple, Google and 7 Other Cash-Hoarding Companies Will Spend Their Billions

It's no secret companies like Apple, Google and Pfizer are sitting on piles of cash. The question is what they plan to do with all that money.

Hospira (HSP) Is Water-Logged And Getting Wetter Today

Hospira (HSP) Is Water-Logged And Getting Wetter Today

Trade-Ideas LLC identified Hospira (HSP) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

The 10 Biggest U.S. M&A Deals in 2015

The 10 Biggest U.S. M&A Deals in 2015

Health care deals dominate the list of big mergers so far this year, while tech comes in second.

New Lifetime High For Hospira (HSP)

New Lifetime High For Hospira (HSP)

Trade-Ideas LLC identified Hospira (HSP) as a new lifetime high candidate

Trade-Ideas: Hospira (HSP) Is Today's

Trade-Ideas: Hospira (HSP) Is Today's "Barbarian At The Gate" Stock

Trade-Ideas LLC identified Hospira (HSP) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Antitrust Protections Hardly Provide a 'Road Map' for Merger Challenges, Regulators Say

Antitrust Protections Hardly Provide a 'Road Map' for Merger Challenges, Regulators Say

It's a myth that regulators rely on covenants allocating antitrust risk for merger investigations; such agreements hardly play a role in the government analysis of a competition threat, regulators say.

When Should You Sell Your Kraft, Alcatel or Hospira Stock?

When Should You Sell Your Kraft, Alcatel or Hospira Stock?

On the heels of Nokia's proposed Alcatel Lucent purchase, here's a closer look at what to do with a stock after a M&A, regardless of whether you already own it.

First-Quarter Deals Near $1 Trillion Mark Highest Value Since 2007

First-Quarter Deals Near $1 Trillion Mark Highest Value Since 2007

Mega deals from strategic players across a variety of industries pushed first-quarter deals to the highest value since 2007.

Hospira (HSP) Is Water-Logged And Getting Wetter Today

Hospira (HSP) Is Water-Logged And Getting Wetter Today

Trade-Ideas LLC identified Hospira (HSP) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

These 10 Pharma and Health Care Stocks Were the Best S&P 500 Performers Last Quarter

These 10 Pharma and Health Care Stocks Were the Best S&P 500 Performers Last Quarter

Health care is a hot investment sector, but some of the industry's best performers last quarter included well-known big benefits companies.

These 10 S&P 500 Stocks Were the Best Performers in the First Quarter

These 10 S&P 500 Stocks Were the Best Performers in the First Quarter

What do Kohl's, First Solar and Kraft Foods have in common? They are among the best performing stocks in 2015.

Jim Cramer's 'Mad Money' Recap: My Best and Worst of the First Quarter

Jim Cramer's 'Mad Money' Recap: My Best and Worst of the First Quarter

This market is leaving a bad taste in the mouths of many investors, Cramer says.

Valeant Boosts Offer for Salix to $15.8 Billion, Endo Drops Bid

Valeant Boosts Offer for Salix to $15.8 Billion, Endo Drops Bid

Valeant comes out on top, following a competing bid from Endo International for the gastrointestinal drugmaker Salix.

3 High-Dividend Stocks That Can Handily Beat the Market

3 High-Dividend Stocks That Can Handily Beat the Market

Investors can grow their portfolios with this simple and effective strategy: Buy, forget and collect.

Valeant Pharmaceuticals Buys Salix Pharmaceuticals in $14.5 Billion Megadeal

Valeant Pharmaceuticals Buys Salix Pharmaceuticals in $14.5 Billion Megadeal

Following last year's failed attempt to purchase Allergan, the Canadian pharmaceutical giant continues its acquisition strategy with its latest deal.

HOSPIRA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of The Hospira, Inc. (HSP) Board Of Directors In Connection To The Proposed Sale Of The Company To Pfizer, Inc.

HOSPIRA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of The Hospira, Inc. (HSP) Board Of Directors In Connection To The Proposed Sale Of The Company To Pfizer, Inc.

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Hospira, Inc.

SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Commences An Investigation Of The Board Of Directors Of Hospira Inc. Regarding The Fairness Of The Sale Of The Company To Pfizer - HSP

SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Commences An Investigation Of The Board Of Directors Of Hospira Inc. Regarding The Fairness Of The Sale Of The Company To Pfizer - HSP

The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Hospira Inc.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Hospira, Inc. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Hospira, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Hospira,...

Jim Cramer on the Stock Market: Spinoffs Are in Vogue

Jim Cramer on the Stock Market: Spinoffs Are in Vogue

The logic of owning the pure play is attractive.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Hospira, Inc. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Hospira, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Hospira,...

Analysts Weigh In On Pfizer Inc Following Acquisition Announcement Of Hospira

Analysts Weigh In On Pfizer Inc Following Acquisition Announcement Of Hospira

Pfizer’s stock jumped 3% in trading on Thursday morning following the company’s announcement on February 5th to acquire fellow pharmaceutical company, Hospira for $17 billion. Sign up for¿...

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of Hospira, Inc. Stockholders

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of Hospira, Inc. Stockholders

Kirby McInerney LLP is investigating potential claims against Hospira, Inc.